Genetic risk models and variant classification tools are refining breast cancer risk assessment by identifying high-risk ...

The SERENA-6 trial shows a 54% reduced risk of death with camizestrant, with a median PFS of 16.6 months versus 9.2 months ...

A preoperative low-energy, high-protein diet led to significant weight loss and improved postoperative symptoms in colorectal ...

A late-breaking presentation at the American Society of Hematology (ASH) 2025 meeting revealed promising phase 3 findings for ...

Innovative smart pill bottles significantly enhance adherence to oral adjuvant endocrine therapy in early-stage breast cancer ...

For adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), the steepest barriers to high-quality care ...

AMCP Nexus 2025 explored innovative health care policies, oncology advancements, and the impact of new regulations on patient ...

Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new ...

With neither health care plan receiving the required votes from the Senate today, there are only 3 weeks for Congress to come up with a solution to the ACA premiums expiring in the new year. Should no ...

The proposed legislation seeks to extend ACA subsidies, extend open enrollment, and lower out-of-pocket caps to prevent ...

T-DXd regimens improved pathologic complete response and safety profiles compared to ddAC-THP in high-risk, HER2-positive early breast cancer. Patient-reported outcomes showed better physical ...

Innovative smart pill bottles significantly enhance adherence to oral adjuvant endocrine therapy in early-stage breast cancer, noted Steven Manobianco, MD.